In the sector press
The fat, drugged, drunk elephant in the room
Kate Rogers, Portfolio Director and Head of Policy at Cazenove Charities shares her thoughts on issues faced by the charity sector in Third Sector Magazine every other month.
We do not know how the economy and markets will cope with the removal of quantitative easing and what the aftershocks might be, writes Kate Rogers
Investment managers are accomplished at looking to the future and appearing confident about what might be around the corner. We use sometimes complicated, sometimes simple models to tell us the likely direction of markets - if interest rates are up, bond prices go down, if corporate earnings are better, equity markets are better, and so on.
But with every confident forecast there are always unknowns, and at the moment the metaphorical elephant in the room is quantitative easing. Central banks in the UK, US, Europe and Japan have all used quantitative easing to try to stimulate the economy. This is done by buying financial assets, such as government bonds, from banks and other institutions, thereby supporting prices and lowering yields. Low yields act as a stimulus by encouraging spending and investment in higher-yielding assets (such as equities) and penalising those holding cash. An almost unfathomable amount of money has been pumped into markets in this manner over the past five years. In the UK alone, the Bank of England's quantitative easing programme has totalled £375bn.
In the aftermath of the financial crisis, it was vital that central banks took steps to prevent a banking meltdown. Quantitative easing achieved this aim and has undoubtedly also supported asset prices. Despite this initial success, it is worth remembering that this is nothing short of the biggest policy experiment that we have seen in our lifetimes. We do not know how the economy and markets will cope with the removal of this stimulus and what the aftershocks might be.
As is the City's custom, there have been numerous analogies. The US analyst Peter Boockvar likens the effect of quantitative easing to beer goggles: for those unfamiliar with the term, the Urban Dictionary defines it as the phenomenon by which one's consumption of alcohol makes alluring a person whom one would usually find unattractive. Or, as the president of the Dallas Federal Reserve wrote: "Things often look better when one is under the influence of free-flowing liquidity."
Another oft-used analogy is that quantitative easing is akin to putting the economy on a highly addictive painkiller: hence tapering - the removal of this stimulus - is like weaning the economy off this drug. But this suggests that the addiction can be cured and the drug removed from the system: I fear it is not that simple.
Perhaps a better analogy might be that suggested by Richard Jeffrey, chief investment officer of the financial management firm Cazenove Capital: he likens quantitative easing to feeding someone with an abnormally high carbohydrate diet. The person might have more energy, but will build up significant amounts of fat - partly visible, but also around vital internal organs. Once the diet has ended, the person might appear to have shed some weight, but the fat in the body remains dangerous and, in the wrong circumstances, can have severe consequences.
These analogies are by no means perfect, but they emphasise the challenge that the policymakers face and the uncertain landscape for investors. The main threat is higher levels of inflation, which could be damaging for charity investors. It is inflation that erodes the ability of a charity to maintain its charitable impact over the long term and threatens the real value of the endowments or foundations. The drunken elephant in the room needs to be watched, not ignored.
This article first appeared in Third Sector on 25 February 2014
For this and other articles by Kate Rogers visit the Third Sector website.
The opinions contained herein are those of the author and do not necessarily represent the house view. This document is intended to be for information purposes only. The material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The material is not intended to provide, and should not be relied on for, accounting, legal or tax advice, or investment recommendations. Information herein is believed to be reliable but Cazenove Capital does not warrant its completeness or accuracy. No responsibility can be accepted for errors of fact or opinion. This does not exclude or restrict any duty or liability that Cazenove Capital has to its customers under the Financial Services and Markets Act 2000 (as amended from time to time) or any other regulatory system. Cazenove Capital is part of the Schroder Group and a trading name of Schroder & Co. Limited 12 Moorgate, London, EC2R 6DA. Authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. For your security, communications may be taped and monitored.